Recursion Pharmaceuticals Inc
RXRX5.030USD
-0.370-6.85%
收盘 06/27, 16:00（美东）报价延迟15分钟
2.04B总市值
亏损市盈率 TTM
关于 Recursion Pharmaceuticals Inc 公司
Recursion Pharmaceuticals, Inc. 是一家临床阶段的 TechBio 公司，致力于解码生物学，实现药物研发的工业化。其 Recursion 操作系统 (OS) 是一个跨多种技术构建的平台，使公司能够映射和导航 Recursion 数据宇宙中的数万亿生物和化学关系。该公司将物理和数字组件集成为原子和比特的迭代循环，将湿实验室生物学和化学数据组织成良性循环，并使用计算工具将计算机假设快速转化为经过验证的见解和新颖的化学反应。其临床项目包括 REC-994、REC-2282、REC-4881 和 REC-3964。REC-994 是一种口服生物可利用的超氧化物清除剂小分子，正在开发用于治疗有症状的脑海绵状畸形 (CCM)。 REC-2282 用于潜在治疗 2 型神经纤维瘤病。REC-3964 用于预防复发性艰难梭菌感染。
公司简介
公司代码RXRX
公司名称Recursion Pharmaceuticals Inc
上市日期Apr 16, 2021
成立日期2013
CEODr. Christopher Gibson, Ph.D.
员工数量840
证券类型Ordinary Share
年结日Apr 16
公司地址41S Rio Grande Street
城市SALT LAKE CITY
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编84101
电话13852690203
网址https://www.recursion.com/
公司代码RXRX
上市日期Apr 16, 2021
成立日期2013
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
Director, Chief Research and Development Officer, Chief Commercial Officer
Director, Chief Research and Development Officer, Chief Commercial Officer
14.63K
-20.60%
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.19M
+0.69%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
166.43K
-4.07%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
142.54K
-20.25%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
132.89K
+19.86%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
91.71K
+31.59%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+30.12%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月28日 周三
更新时间: 5月28日 周三
持股股东
股东类型
持股股东
持股股东
占比
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
持股股东
持股股东
占比
ARK Investment Management LLC
8.71%
The Vanguard Group, Inc.
8.06%
Baillie Gifford & Co.
6.10%
BlackRock Institutional Trust Company, N.A.
5.02%
SB Global Advisers Ltd
3.67%
Other
68.43%
股东类型
持股股东
占比
Investment Advisor
36.58%
Investment Advisor/Hedge Fund
19.62%
Venture Capital
8.74%
Sovereign Wealth Fund
4.12%
Individual Investor
3.17%
Research Firm
2.16%
Hedge Fund
2.01%
Corporation
1.93%
Bank and Trust
0.86%
Other
20.83%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
637
324.02M
81.93%
+29.39M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
2023Q2
358
172.49M
89.73%
-20.74M
2023Q1
345
171.25M
93.19%
-16.02M
2022Q4
321
167.85M
92.66%
-946.19K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
ARK Investment Management LLC
32.35M
8.19%
-422.79K
-1.29%
Dec 31, 2024
The Vanguard Group, Inc.
33.97M
8.6%
+9.74M
+40.18%
Dec 31, 2024
Baillie Gifford & Co.
24.86M
6.29%
-375.81K
-1.49%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.31M
5.14%
+2.56M
+14.39%
Dec 31, 2024
SB Global Advisers Ltd
14.67M
3.71%
+14.67M
--
Dec 31, 2024
Kinnevik AB
11.91M
3.01%
--
--
Dec 31, 2024
State Street Global Advisors (US)
12.58M
3.18%
-291.91K
-2.27%
Dec 31, 2024
Mubadala Investment Company PJSC
12.99M
3.29%
--
--
Dec 31, 2024
DCVC Management Co, LLC
5.94M
1.5%
-3.73M
-38.55%
Dec 31, 2024
Novo Holdings A/S
10.11M
2.56%
+10.11M
--
Dec 31, 2024
查看更多
持股ETF
更新时间: 6月6日 周五
更新时间: 6月6日 周五
机构名称
占比
ARK Genomic Revolution ETF
4.95%
ARK Innovation ETF
1.5%
First Trust Nasdaq AI and Robotics ETF
1.01%
AXS Green Alpha ETF
0.81%
Franklin Genomic Advancements ETF
0.66%
WisdomTree BioRevolution Fund
0.64%
Main Thematic Innovation ETF
0.59%
SPDR S&P Biotech ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.37%
查看更多
ARK Genomic Revolution ETF
占比4.95%
ARK Innovation ETF
占比1.5%
First Trust Nasdaq AI and Robotics ETF
占比1.01%
AXS Green Alpha ETF
占比0.81%
Franklin Genomic Advancements ETF
占比0.66%
WisdomTree BioRevolution Fund
占比0.64%
Main Thematic Innovation ETF
占比0.59%
SPDR S&P Biotech ETF
占比0.56%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.45%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.37%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
